p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer

Administration of the microtubule inhibitor docetaxel is a common treatment for metastatic castration-resistant prostate cancer (mCRPC) and results in prolonged patient overall survival. Usually, after a short period of time chemotherapy resistance emerges and there is urgent need to find new therap...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocr Relat Cancer
Main Authors: Gruber, Martina, Ferrone, Lavinia, Puhr, Martin, Santer, Frédéric R, Furlan, Tobias, Eder, Iris E, Sampson, Natalie, Schäfer, Georg, Handle, Florian, Culig, Zoran
Formato: Artigo
Idioma:Inglês
Publicado em: Bioscientifica Ltd 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7040497/
https://ncbi.nlm.nih.gov/pubmed/31951590
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-19-0488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados